2013年7月16日訊 /生物谷BIOON/ --雅培（Abbott）7月15日宣布，將支付5.6億美元收購2家私人控股公司——Idev Technologies公司和OptiMedica公司，前者專注于冠狀動脈植入物，后者專注于激光輔助眼科手術。這2筆收購，將有助于雅培擴充其醫(yī)療設備產品。
雅培稱，將支付3.1億美元的現(xiàn)金及債務收購總部位于美國得克薩斯州韋伯斯特市的Idev Technologies公司，該公司上市了一款支架（stent）Superva Veritas，這是一款自膨脹（self-expanding）網(wǎng)狀管支架，已在歐洲上市，用于治療四肢堵塞。該支架能夠促進血液的流動，尤其是大腿和膝蓋血管中的血液流動。在美國，該支架上市用于治療癌癥導致的膽管狹窄。
該筆交易預計將在今年年底完成，同時將不會影響雅培的年度指南。目前，雅培已經(jīng)在銷售一款最暢銷的藥物涂層支架Xience，用于冠狀動脈疾病患者的治療。
在另一項聲明中，雅培宣布，將支付2.5億美元現(xiàn)金收購位于美國硅谷的OptiMedica公司，該公司制造了一款計算機化的激光器（computerized laser），用于白內障手術。同時，雅培將支付高達1.5億美元的里程碑款項，包括達到特定的銷售目標及監(jiān)管目標的里程碑款項。
OptiMedica公司的催化劑活性精密激光系統(tǒng)（Catalys Precision Laser System）代替了白內障手術過程中在更換晶狀體（len）時所需的外科醫(yī)生的手動操作步驟。
白內障手術包括移除渾濁的晶狀體及植入人工晶狀體。根據(jù)行業(yè)數(shù)據(jù)，2013年在全球范圍內將開展近2200萬例白內障手術。
Leerink Swann分析師Danielle Antalffy在一份報告中稱，這2筆收購是“積極的戰(zhàn)略（positive strategically）”，但她同時指出，雅培目前正面臨著來自全球經(jīng)濟疲軟的壓力，尤其是在中國的營養(yǎng)品銷售壓力。（生物谷Bioon.com）
英文原文：Abbott Labs to pay $560M to acquire private companies focused on stents and laser eye surgery
July 15, 2013 - 11:48 am EDT WASHINGTON — Abbott Laboratories announced Monday it would pay a combined $560 million to acquire two privately-held companies focused on coronary implants and laser-assisted eye surgery.
The acquisitions of Idev Technologies and OptiMedica Corp will help the health care company expand its medical device offerings, a half-year after it spun off its main pharmaceutical offerings into a separate company. In January Abbott completed the spin-off of the drugmaker Abbvie, leaving it with a business model built around generic drugs, medical implants and nutritional formula. Abbvie markets company's branded prescription drugs, including the blockbuster Humira.
Abbott said Monday it will pay $310 million in cash and debt for Webster, Texas-based Idev Technologies, which markets a stent used to treat blockages in the limbs. The stent, called Superva Veritas, is a self-expanding mesh tube marketed in Europe to promote blood flow, particularly in vessels in the thigh and knee. In the U.S. the stent is marketed to treat narrowing of bile ducts caused by cancer.
The transaction is expected to close by the end of the year and will not impact the company's annual guidance. Abbott already sells the best-selling drug-coated stent, Xience, to treat patients with coronary artery disease.
In a separate announcement, Abbott said it would pay $250 million in cash for Silicon Valley-based OptiMedica Corp., which makes a computerized laser used in cataract surgery. Abbott will pay up to $150 million in milestone payments for reaching certain sales and regulatory goals.
OptiMedica's Catalys Precision Laser System replaces some of the manual steps required of surgeons when replacing the lens of the eye during cataract surgery.
Surgery for cataracts involves removing the clouded lens and replacing it with an artificial implant lens. Nearly 22 million cataract procedures will be performed globally in 2013, according to industry figures.
Leerink Swann analyst Danielle Antalffy said in a note that the acquisitions are "positive strategically." However, she noted that Abbott is being pressured by weakness in the global economy, particularly sales of nutritionals in China.
"We remain cautious on 2013 guidance," Antalffy said, reaffirming a "Market Perform" rating for the stock.
In midday trading, shares of North Chicago, Illinois-based Abbott fell 8 cents to $35.23.
